10 Result(s)
within
Jean-Yves Douillard
-
Article
Open AccessClinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study
To validate a next-generation sequencing (NGS)-based companion diagnostic using the MiSeqDx® sequencing instrument to simultaneously detect 56 RAS mutations in DNA extracted from formalin-fixed paraffin-embedded ...
-
Article
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study
Nintedanib is a triple angiokinase inhibitor approved with docetaxel for adenocarcinoma non-small cell lung cancer after first-line chemotherapy (FLT). In the phase III LUME-Lung 1 study, overall survival (OS)...
-
Article
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
Clinical response to bevacizumab varies between patients treated for metastatic colorectal cancer (mCRC). The aim of this study was to quantify individual factors affecting bevacizumab pharmacokinetic variabil...
-
Article
Open AccessPanitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
Tumour biomarker status is being used more and more frequently to guide treatment decisions in patients with metastatic colorectal cancer (mCRC). Continued cycles of hypothesis generation and biomarker testing...
-
Article
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
Objectives To assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with metastatic colorectal cancer who had failed one or two previous chemotherapeutic regimens that included ...
-
Article
Open AccessMechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
Several proteins that promote angiogenesis are overexpressed in hepatocellular carcinoma (HCC) and have been implicated in disease pathogenesis. Sunitinib has antiangiogenic activity and is an oral multitarget...
-
Article
A Clinical Pharmacokinetic Analysis of Tegafur-Uracil (UFT) Plus Leucovorin Given in a New Twice-Daily Oral Administration Schedule
Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer. The aim of this phase II, crossover, bioequivalence study was to compare the pharmacokinetics (primary objective) and tolerab...
-
Article
Standards, Options et Recommandations pour le traitement périopératoire des patients atteints d’un cancer bronchique non à petites cellules résécable d’emblée, opérables (mise à jour), rapport abrégé
La mise à jour des recommandations pour la pratique clinique (RPC) pour le traitement périopératoire des patients atteints d’un cancer bronchique non à petites cellules résécable d’emblée, opérables a été élab...
-
Article
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie
Interleukin-2 (IL2) or/and interferon (IFN) are routinely used for treating patients with metastatic renal cell cancer. However, results are disappointing since most patients experience treatment failure. With...
-
Article
Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon γ
Fifteen patients with metastatic gastrointestinal adenocarcinomas were treated with low doses of recombinant human interferon γ (rh-IFNγ) and a mixture of monoclonal antibodies (mAb) that bind to tumor cells. ...
